Mereo BioPharma Group (MREO) Stock Price, News & Analysis

Company Overview

Mereo BioPharma Group plc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for rare diseases, oncology and severe respiratory conditions. The company pursues an asset‐centric model, in which it in-licenses or acquires clinical-stage small molecules and monoclonal antibodies with established safety profiles. By concentrating resources on a select number of programs, Mereo aims to accelerate proof-of-concept studies and maximize the potential value of each therapeutic candidate.

Mereo’s pipeline includes investigational therapies for skeletal disorders, such as setrusumab (BPS-804) for osteogenesis imperfecta, and treatments for acute and chronic respiratory diseases. Additional clinical programs target oncology and immunology indications, leveraging both internally developed molecules and partnerships with third-party biotech and pharmaceutical companies. The company conducts multi‐center trials in Europe and North America, collaborating with academic institutions and contract research organizations to advance its clinical objectives.

Established in 2013 and headquartered in London, Mereo BioPharma has built a team with expertise in clinical development, regulatory affairs and corporate strategy to support its focused portfolio. The company’s business strategy emphasizes strategic alliances, out-licensing opportunities and selective acquisitions to enhance shareholder value and ensure sustained progress across its pipeline. Mereo is listed on the NASDAQ under the ticker symbol MREO and maintains operations in the United Kingdom, United States and Europe.

Key Stats

• Today's Range: $1.96 to $2.11
• 50-Day Range: $1.52 to $2.10
• 52-Week Range: $1.47 to $4.72
• Volume: 1.08 million shs
• Average Volume: 1.33 million shs
• Market Capitalization: $311.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.40
• Consensus Rating: Moderate Buy

Mereo BioPharma Group Stock Analysis - MarketRank™

Mereo BioPharma Group scored higher than 42% of companies evaluated by MarketBeat, and ranked 684th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Mereo BioPharma Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Mereo BioPharma Group has a consensus price target of $7.40, representing about 277.6% upside from its current price of $1.96.

Amount of Analyst Coverage

Mereo BioPharma Group has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Mereo BioPharma Group are expected to decrease in the coming year, from ($0.03) to ($0.04) per share.

Price to Book Value per Share Ratio

Mereo BioPharma Group has a P/B Ratio of 5.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.94% of the outstanding shares of Mereo BioPharma Group have been sold short.

Short Interest Ratio / Days to Cover

Mereo BioPharma Group has a short interest ratio ("days to cover") of 5.1.

Change versus previous month

Short interest in Mereo BioPharma Group has recently decreased by 2.21%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mereo BioPharma Group does not currently pay a dividend.

Dividend Growth

Mereo BioPharma Group does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.94% of the outstanding shares of Mereo BioPharma Group have been sold short.

Short Interest Ratio / Days to Cover

Mereo BioPharma Group has a short interest ratio ("days to cover") of 5.1.

Change versus previous month

Short interest in Mereo BioPharma Group has recently decreased by 2.21%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.62

News Sentiment

Mereo BioPharma Group has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Mereo BioPharma Group this week, compared to 3 articles on an average week.

Search Interest

52 people have searched for MREO on MarketBeat in the last 30 days. This is an increase of 333% compared to the previous 30 days.

MarketBeat Follows

4 people have added Mereo BioPharma Group to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Mereo BioPharma Group insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.50% of the stock of Mereo BioPharma Group is held by insiders.

Percentage Held by Institutions

62.83% of the stock of Mereo BioPharma Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MREO Stock Analysis - Frequently Asked Questions

How have MREO shares performed this year?

Mereo BioPharma Group's stock was trading at $3.50 at the beginning of 2025. Since then, MREO stock has decreased by 44.0% and is now trading at $1.96.

How were Mereo BioPharma Group's earnings last quarter?

Mereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO) announced its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by $0.01. The company earned $0.50 million during the quarter, compared to analyst estimates of $7.80 million.

When did Mereo BioPharma Group IPO?

Mereo BioPharma Group (MREO) raised $49 million in an initial public offering on the week of April 23rd 2018. The company issued 2,800,000 shares at $17.62 per share. Cowen, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and JMP Securities and Cantor Fitzgerald Europe were co-managers.

How do I buy shares of Mereo BioPharma Group?

Shares of MREO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Mereo BioPharma Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mereo BioPharma Group investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), e.l.f. Beauty (ELF), Disc Medicine (IRON), Jabil (JBL) and Builders FirstSource (BLDR).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 10/12/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MREO
• CIK: 1719714
• Web: www.mereobiopharma.com
• Phone: 44-33-3023-7300
• Fax: N/A
• Employees: 40
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Mereo BioPharma Group: $7.40
• High Price Target: $10.00
• Low Price Target: $5.00
• Potential Upside/Downside: +277.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$43.25 million
• Net Margins: N/A
• Pretax Margin: -9,910.00%
• Return on Equity: -80.00%
• Return on Assets: -66.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.13
• Quick Ratio: 8.13

Sales & Book Value

• Annual Sales: $10 million
• Price / Sales: 31.16
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.39 per share
• Price / Book: 5.03

Miscellaneous

• Outstanding Shares: 159,000,000
• Free Float: 150,255,000
• Market Cap: $311.64 million
• Optionable: Optionable
• Beta: 0.45